Company Summary - Allergy Therapeutics PLC (LSE:AGY)
11.75p
0.00p
FTSE AIM All Share Pharmaceuticals & BiotechnologyMarket cap: £36.516m
NEW Explore our new and improved report for Allergy Therapeutics PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Pharmaceutical company focused upon the treatment and prevention of allergy
| Financials - Annual Report (30/06/2011) | ||
|---|---|---|
| Turnover | £m | 41.55 |
| Pre-tax Profit | £m | -2.31 |
| EPS | p | -0.92 |
| DPS | p | - |
| Dividend Yield | % | |
| Director | Board Role |
|---|---|
| Peter Jensen | Chairman |
| Manuel Llobet | Chief Executive |
| Ian Postlethwaite | Finance Director & Company Sec |
Products Brands & Subsidiaries
Products & Brands
Anapen; Oralvac Compact; Pollinex Grasses & Rye; Pollinex Quattro; Pollinex TA Mix top; PollinexTrees; Tyrosine TU; Venomil
Subsidiaries
Bencard Allergie GmbH; Bencard Allergie (Austria) GmbH; Allergy Therapeutics (Holdings) Ltd; Allergy Therapeutics (UK) Ltd...
Broker Sentiment (2 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Regulatory update PEI FDA | 28/11/2011 |
| AGM Statement | 16/11/2011 |
| Annual Financial Report | 20/10/2011 |
For more information
and investor relations, visit the
Allergy Therapeutics PLC company website: